In the journals: Hormone therapy: Gallbladder risk is lower with a patch than a pill
In the journals
About half the women in the study took HT, either currently (32%) or in the past (18%). Of those, 77% took oral estrogen and 18% transdermal estrogen (5% used an implant or other form). Compared with women who had never taken HT, current users were 64% more likely to develop gallbladder disease. Past users had a 27% higher risk, suggesting that estrogen use may cause a lasting change in the gallbladder. Among oral HT users, the risk of gallstones was greater with higher doses, and greater with equine estrogens (Premarin, or, when combined with a progestin, Prempro) than with estradiol. Adding a progestin to estrogen did not appear to affect the risk. The surprise came when researchers compared women taking oral HT with those using transdermal HT: the rate of hospital admissions for gallbladder disease or surgery was about 55% lower among women using the transdermal form.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
